Updated

Moderna and Merck released top-line results on October 22, 2026 showing their experimental mRNA cancer vaccine reduced death and recurrence rates by 42% in trial participants. The announcement follows the companies' earlier disclosure that the trial had met its success criteria. The results mark a significant milestone for mRNA-based cancer immunotherapy, building on technology first proven effective in COVID-19 vaccines, and could pave the way toward regulatory approval of a new class of personalized cancer treatments.